Literature DB >> 11436924

Self-reported abstinence effects in the first month after smoking cessation.

M M Ward1, G E Swan, L M Jack.   

Abstract

The present study evaluated self-reported subjective complaints (29 single items and 11 scales) at precessation, on quit day, and on Days 1, 2, 3, 7, 14, 21, and 28 after cessation in 46 healthy quitters who remained abstinent for the first month after cessation (biochemically confirmed). Also tested on the same schedule were 29 nonsmokers matched for age and gender. Specific criteria were set for transient and offset effects based on the direction, magnitude, and time course of changes in symptoms after cessation. Results indicated that single-item anger, anxiety, depression, difficulty concentrating, irritability, restlessness, dizziness, and nausea, and the Shiffman-Jarvik Stimulation/Sedation Subscale, the Perceived Stress scale, and the POMS anger, confusion, and tension subscales met the criteria for transient effects, and that single-item desire to smoke, cough, and headache, and the Shiffman-Jarvik Psychological Subscale met the criteria for offset effects. These findings help to clarify which subjective complaints after smoking cessation are transient effects and which are offset effects, a distinction with important implications for understanding nicotine dependence and for designing pharmacological and nonpharmacological interventions for smoking cessation.

Entities:  

Mesh:

Year:  2001        PMID: 11436924     DOI: 10.1016/s0306-4603(00)00107-6

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  27 in total

1.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

2.  The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation.

Authors:  Thomas J Gould; George S Portugal; Jessica M André; Matthew P Tadman; Michael J Marks; Justin W Kenney; Emre Yildirim; Michael Adoff
Journal:  Neuropharmacology       Date:  2012-01-21       Impact factor: 5.250

3.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

4.  Anger and psychobiological changes during smoking abstinence and in response to acute stress: prediction of smoking relapse.

Authors:  Mustafa al'Absi; Steven B Carr; Stephan Bongard
Journal:  Int J Psychophysiol       Date:  2007-05-03       Impact factor: 2.997

5.  Negative Affect-Related Factors Have the Strongest Association with Prescription Opioid Misuse in a Cross-Sectional Cohort of Patients with Chronic Pain.

Authors:  Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

6.  Patterns of change in affect and adrenocortical activity over an extended period of smoking abstinence.

Authors:  Motohiro Nakajima; Mustafa al'Absi
Journal:  Psychol Addict Behav       Date:  2013-10-14

7.  Markov model of smoking cessation.

Authors:  Peter R Killeen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-20       Impact factor: 11.205

8.  A Control Theory Model of Smoking.

Authors:  Georgiy Bobashev; John Holloway; Eric Solano; Boris Gutkin
Journal:  Methods Rep RTI Press       Date:  2017-06

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.

Authors:  David Gonzales; Douglas E Jorenby; Thomas H Brandon; Carmen Arteaga; Theodore C Lee
Journal:  Addiction       Date:  2010-09-01       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.